Eptifibatide keeps pace with abciximab in STEMI

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1613, 2007-01, pp. : 5-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Amiodarone keeps pace with ICD therapy

By  

Inpharma, Vol. 1, Iss. 1268, 2000-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

BRAVE researchers say abciximab of no benefit in PCI for STEMI

By  

Inpharma, Vol. 1, Iss. 1632, 2008-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Clinical outcomes are similar for abciximab and eptifibatide in patients who undergo percutaneous coronary intervention (PCI), but abciximab is associated with greater costs

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 493, 2005-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Clinical outcomes are similar for abciximab and eptifibatide in patients who undergo percutaneous coronary intervention (PCI), but abciximab is associated with greater costs

By  

Inpharma, Vol. 1, Iss. 1518, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

IIb

By  

Current Drug Targets, Vol. 16, Iss. 13, 2015-12 ,pp. : 1429-1437

Bentham Science Publishers

Access to resources Recommend Favorite